Eli Lilly and Company

NYSE:LLY

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 696.15 B

Share Price

USD 775.45

Avg Daily Volume

4,188,687

Change (1 day)

-2.47%

Change (1 year)

-14.70%

Change (YTD)

0.45%

Eli Lilly and Company Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD 54.43

Eli Lilly and Company Revenue Per Share is USD 54.43 for the Trailing 12 Months (TTM) ending March 31, 2025, a 36.54% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Eli Lilly and Company Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 39.86, a 31.44% change year over year.
Eli Lilly and Company Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 30.33, a -6.24% change year over year.
Eli Lilly and Company Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 32.35, a 15.21% change year over year.
Eli Lilly and Company Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 28.07, a 12.50% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio

NYSE: LLY

Eli Lilly and Company

CEO	Mr. David A. Ricks
IPO Date	June 1, 1972
Location	United States
Headquarters	Lilly Corporate Center
Employees	47,000
Sector	🏥 Health Care
Industries Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.